The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Actinium Receives Assignment of Intellectual Property from Memorial Sloan Kettering Cancer Center

12-Jul-2016 | Source : Actinium Pharmaceuticals | Visits : 5676
NEW YORK, NY - Actinium Pharmaceuticals Inc., a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today in a press release that the Company has been assigned two provisional patent applications from Memorial Sloan-Kettering Cancer Center (MSK).

The Company's License, Development and Commercialization Agreement (License Agreement) with MSK, which already included issued patents that pertain to Actinium's Alpha Particle Immunotherapy (APIT) technology platform and drug preparation methods now includes these newly assigned provisional patent applications. 

Kaushik J. Dave, Ph.D., MBA, Actinium's Chief Executive Officer said, "These provisional patent applications are a welcome addition to Actinium's intellectual property portfolio. We have been focused on the development of intellectual property on the production of Actinium-225, linking technologies that can be used in our APIT platform and methods of use and these provisional patents represent the potential extension of our IP beyond 2035." 

The two provisional patent applications assigned to Actinium from MSK pertain to the labeling of monoclonal antibodies with Actinium-225 and the application of these Actinium-225 enabled antibodies for treating cancers. Actinium-225 is an alpha-emitting isotope used in the Company's drug candidate Actimab-A, which is intended to treat patients newly diagnosed with Acute Myeloid Leukemia (AML) over the age of 60. Actimab-A is a second generation therapy from Actinium's HuM195-alpha program, which has been studied in almost 90 patients in four clinical trials. Actinium's intellectual property portfolio consists of wholly-owned and licensed issued and pending patents related to isotope production methods, drug preparation methods specific to the labeling of anitobodies with Actinium-225, monocloncal antibody composition and production and the use of Actinium's technology in the treatment of cancer. 

Sandesh Seth, Actinium's Executive Chairman stated, "We are pleased to announce these two additional provisional patent applications and thank Memorial Sloan Kettering Cancer Center for their continued efforts as part of our collaboration. Our APIT platform and Actinium-225 are strategically important assets to the Company that we believe will be of interest to biopharmaceutical companies seeking to enhance their antibody programs and therefore represents significant potential value to our shareholders. Most importantly, they represent potential new therapies that could improve the lives of the patients we are focused on improving through the development of targeted radioimmunotherapies." 

Related Articles